Compound 114 (D3R/MOR antagonist 1) exhibits dual antagonistic activity at dopamine D3 receptors (D3R) and mu-opioid receptors (MOR), with K i values of 46.5 nM and 691 nM, respectively. It offers analgesic benefits through partial agonism at MOR and may decrease the risk of opioid misuse through its D3R antagonistic properties [1].
Molecular Weight:
420.38
Formula:
C22H27Cl2N3O
Target:
Dopamine Receptor|||Opioid Receptor
* VAT and and shipping costs not included. Errors and price changes excepted
